Effect of celecoxib plus standard chemotherapy on serum levels of vascular endothelial growth factor and cyclooxygenase‑2 in patients with gastric cancer

Zhou Y, Zhang Z, Zhang Z, et al: A rising trend of gastric cardia cancer in Gansu Province of China. Cancer Lett. 269:18–25. 2008. View Article : Google Scholar : PubMed/NCBI

Qin X and Liu FL: Efforts to improve postoperative 5-year survival rate of gastric cancer. Journal of Surgery Concepts and Practice. 13:4–6. 2008.(In Chinese).

Dicken BJ, Bigam DL, Cass C, et al: Gastric adenocarcinoma: review and considerations for future directions. Ann Surg. 241:27–39. 2005.PubMed/NCBI

Yao L, Liu F, Hong L, et al: The function and mechanism of COX-2 in angiogenesis of gastric cancer cells. J Exp Clin Cancer Res. 30:132011. View Article : Google Scholar : PubMed/NCBI

Liu H, Huang P, Xu X, et al: Anticancer effect of celecoxib via COX-2 dependent and independent mechanisms in human gastric cancers cells. Dig Dis Sci. 54:1418–1424. 2009. View Article : Google Scholar : PubMed/NCBI

Zhang DQ, Guo Q, Zhu JH, et al: Increase of cyclooxygenase-2 inhibition with celecoxib combined with 5-FU enhances tumor cell apoptosis and antitumor efficacy in a subcutaneous implantation tumor model of human colon cancer. Word J Surg Oncol. 11:162013. View Article : Google Scholar

Gou HF, Chen XC, Zhu J, et al: Expression of COX-2 and VEGF-C in gastric cancer: correlations with lymphangiogenesis and prognostic implications. J Exp Clin Cancer Res. 30:142011. View Article : Google Scholar : PubMed/NCBI

Da MX, Wu XT, Wang J, et al: Expression of cyclooxygenase-2 and vascular endothelial growth factor-C correlates with lymphangiogenesis and lymphatic invasion in human gastric cancer. Arch Med Res. 39:92–99. 2008. View Article : Google Scholar : PubMed/NCBI

Leung WK, To KF, Go MY, et al: Cyclooxygenase-2 upregulates vascular endothelial growth factor expression and angiogenesis in human gastric carcinoma. Int J Oncol. 23:1317–1322. 2003.PubMed/NCBI

Kolev Y, Uetake H, Iida S, et al: Prognostic significance of VEGF expression in correlation with COX-2, microvessel density, and clinicopathological characteristics in human gastric carcinoma. Ann Surg Oncol. 14:2738–2747. 2007. View Article : Google Scholar

Kuo CH, Hu HM, Tsai PY, et al: Short-term celecoxib intervention is a safe and effective chemopreventive for gastric carcinogenesis based on a Mongolian gerbil model. World J Gastroenterol. 15:4907–4914. 2009. View Article : Google Scholar : PubMed/NCBI

Hu PJ, Yu J, Zeng ZR, et al: Chemoprevention of gastric cancer by celecoxib in rats. Gut. 53:195–200. 2004. View Article : Google Scholar : PubMed/NCBI

Zhu FS, Chen XM, Wang YJ, Zhang X and Feng JX: Antitumor effects of specific cyclooxygenase inhibitors combined with chemotherapeutic agents on gastric cancer cells in vitro. Chin J Oncol. 29:186–188. 2007.(In Chinese).

Allegrini G, Di Desidero T, Barletta MT, et al: Clinical, pharmacokinetic and pharmacodynamic evaluations of metronomic UFT and cyclophosphamide plus celecoxib in patients with advanced refractory gastrointestinal cancers. Angiogenesis. 15:275–286. 2012. View Article : Google Scholar

Du X, Nie H, Liang Y, et al: The effect of chemotherapy treatment on T cell subgroups, NK cell in patients after radical gastrectomy. Hebei Med J. 32:49–50. 2011.

Yoshida K, Yamaguchi K, Osada S, et al: Challenge for a better combination with basic evidence. Int J Clin Oncol. 13:212–219. 2008. View Article : Google Scholar : PubMed/NCBI

Zhou Y, Ran J, Tang C, et al: Effect of celecoxib on E-cadherin, VEGF, microvessel density and apoptosis in gastric cancer. Cancer Biol Ther. 6:269–275. 2007. View Article : Google Scholar : PubMed/NCBI